Lead Product(s): SLN501
Therapeutic Area: Immunology Product Name: SLN501
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Mallinckrodt Plc
Deal Size: $2,020.0 million Upfront Cash: $20.0 million
Deal Type: Collaboration April 28, 2021
The milestone relates to pre-clinical development work on the SLN500 C3 targeting program, highlighting the successful ongoing collaboration between the two companies.